Moleculin Biotech Stockholders Approve Warrant Share Issuance

Moleculin Biotech ( (MBRX) ) has shared an update.

At a special meeting of stockholders held on April 15, 2026, Moleculin Biotech, Inc. obtained approval to issue up to 6,367,956 shares of common stock upon the exercise of certain warrants issued on February 20, 2026, enhancing the company’s potential to raise additional equity capital. Stockholders also approved a proposal permitting adjournment of the meeting to solicit more proxies if needed, but they failed to pass an amendment to change the company’s name to Moleculin Inc., underscoring that while investors support capital-raising measures, they were less responsive to the proposed corporate rebranding.

The most recent analyst rating on (MBRX) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.

Score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn) and bearish technical signals (below key moving averages with negative MACD). Offsetting these somewhat are positive corporate developments around Annamycin/MIRACLE trial progress and reduced near-term delisting risk; valuation signals are limited given negative earnings and no dividend data.

To see Spark’s full report on MBRX stock, click here.

More about Moleculin Biotech

Moleculin Biotech, Inc. is a biotechnology company whose operations center on the development of drug candidates and related technologies in the life sciences sector. Its business depends heavily on access to equity capital markets, and stockholder approvals for share issuances and corporate actions are a key component of its financial and strategic flexibility.

Average Trading Volume: 159,897

Technical Sentiment Signal: Sell

Current Market Cap: $14.51M

For detailed information about MBRX stock, go to TipRanks’ Stock Analysis page.